据智通财经12月9日报道，知名投资人林园今日现身片仔癀2025年第一次临时股东大会，当被问及是否还坚持片仔癀股票一股不卖？林园回应称："我卖它 干什么？"他还表示："我觉得（片仔癀）这是好东西，找不到。" 公开资料显示，林园从2005年便开始介入持有片仔癀。他还公开表示，"片仔癀是独门生意，他们最终要卖到至2瓶茅台的价格"。 10月28日，据上海证券报报道，林园称自己是片仔癀的消费者，他母亲也是。像这样的标的，全球市场也是不多的。 值得注意的是，片仔癀公布的最新三季报数据难看，2025年前三季度，片仔癀营收为74.42亿元，同比下滑11.93%；归母净利润为21.29亿元，同比下滑 20.74%。同时，今年第三季度存货增至61.6亿元，相较今年初增长了24.02%。 这是近10年来，片仔癀前三季度的营收和净利润首次负增长。 其中，三季度，片仔癀实现营收20.64亿元，同比下降26.28%，实现净利润6.87亿元，同比下降28.82%。 （文章来源：每日经济新闻） | | | 本报告期比 上年同期增 | | 年初全报告 期末比上年 | | --- | --- | --- | --- | --- | | 项目 | ...

据智通财经12月9日报道，知名投资人林园今日现身片仔癀2025年第一次临时股东大会，当被问及是否还坚持片仔癀股票一股不卖？林园回应称："我卖它 干什么？"他还表示："我觉得（片仔癀）这是好东西，找不到。" 公开资料显示，林园从2005年便开始介入持有片仔癀。他还公开表示，"片仔癀是独门生意，他们最终要卖到至2瓶茅台的价格"。 10月28日，据上海证券报报道，林园称自己是片仔癀的消费者，他母亲也是。像这样的标的，全球市场也是不多的。 值得注意的是，片仔癀公布的最新三季报数据难看，2025年前三季度，片仔癀营收为74.42亿元，同比下滑11.93%；归母净利润为21.29亿元，同比下滑 20.74%。同时，今年第三季度存货增至61.6亿元，相较今年初增长了24.02%。 这是近10年来，片仔癀前三季度的营收和净利润首次负增长。 业绩的压力直接反映在股价上。2021年片仔癀市值曾一度突破2900亿元，而截至2025年12月9日收盘，其股价为167.53元/股，已较2021年12月的高点累计 跌去超60%，最新总市值1011亿元，已较高点蒸发1889亿元。 对此，林园曾评论称，"它的波动是行业的问题，不是单一公司的问 ...

泰和泰（北京）律师事务所 关于漳州片仔癀药业股份有限公司 2025 年第一次临时股东大会 法律意见书 泰和泰证字[2025]PZH-02 号 泰和泰（北京）律师事务所 关于漳州片仔癀药业股份有限公司 北京市朝阳区东四环中路 56 号远洋国际中心 A 座 12 层 电话：（010）85865151 传真：（010）85861922 邮政编码：100025 泰和泰（北京）律师事务所关于漳州片仔癀药业股份有限公司 2025 年第一次临时股东大会法律意见书 泰和泰（北京）律师事务所 2025 年第一次临时股东大会法律意见书 泰和泰证字[2025]PZH-02 号 致：漳州片仔癀药业股份有限公司 泰和泰（北京）律师事务所（以下简称"本所"）接受漳州片仔癀药业股份 有限公司（以下简称"公司"）的委托，指派许军利律师、殷庆莉律师对公司 2025 年第一次临时股东大会（以下简称"本次股东大会"）进行见证，并依据《中华 人民共和国公司法》（以下简称"《公司法》"）、中国证券监督管理委员会《上 市公司股东会规则》（以下简称"《股东会规则》"）、《上海证券交易所上市 公司自律监管指引第 1 号——规范运作（2025 年 5 月修订 ...

证券代码：600436 证券简称：片仔癀 公告编号：2025-043 漳州片仔癀药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 1 / 4 表决方式符合《公司法》及《漳州片仔癀药业股份有限公司章程》（以下 简称"《公司章程》"）的规定，公司董事长林志辉先生主持本次会议。大会采用 网络投票和现场投票相结合的方式进行表决。会议的召开和表决程序符合《公司 法》 (五) 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事6人，出席6人，其中独立董事杜守颖女士、陈蕾女士、田 正大先生以通讯方式出席本次会议； (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情 况： | 1、出席会议的股东和代理人人数 | 1,576 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 357,789,820 | | 3、出席会议的股东所持有表决权股份数占公司有表决权 | 59.3037 | | 股份 ...

Group 1 - The core viewpoint is that renowned investor Lin Yuan remains confident in the stock of Pian Zai Huang, indicating he has no intention of selling his shares, describing the product as something valuable and hard to find [1] Group 2 - Lin Yuan's statement at the 2025 first extraordinary general meeting of shareholders emphasizes his strong belief in the company's potential and the uniqueness of its offerings [1]

转自：新华财经 目前，参茸安神丸已进入300多家片仔癀国药堂销售，产品自上市以来，凭借温和调养特性与品牌信任 背书，受到中老年及职场高压人群的广泛关注，复购率稳步提升，市场动销态势良好。 根据中国品牌建设促进会、中国资产评估协会等联合发布的《2025中国品牌价值评价信息发布》，片仔 癀以437.39亿元的品牌价值，位列"中华老字号"类别第一名；并连续多年蝉联胡润医疗健康品牌榜中华 老字号品牌价值榜首。公司此次推出参茸安神丸，不仅是产品线的自然延伸，更是深化大健康战略布局 的重要体现。未来，片仔癀将继续以匠心守正、以科技赋能，依托资本优势、科研平台与品牌势能，打 造更多安全、有效、可信赖的健康产品，助力构建具有中国特色的预防为主、防治结合的全民健康服务 体系。 本文内容仅为药品及相关健康知识的科普介绍，旨在提供一般性信息参考，不构成任何形式的专业医疗 建议、诊断或治疗方案。如有任何健康问题，请务必咨询合格的医疗卫生专业人员，并严格遵守医嘱。 编辑：王姝睿 随着人们生活节奏加快、工作压力增大，失眠、焦虑、健忘、心悸等亚健康状态日益普遍，"养心安 神"已成为大健康市场的重要增长点。据中国睡眠研究会《2025年中国睡 ...

Core Viewpoint - The Chinese traditional medicine sector is experiencing increased activity due to a surge in flu cases, with the Chinese Medicine ETF (560080) showing a slight decline but still attracting investor interest [1][9]. Market Performance - The Chinese Medicine ETF (560080) closed down 0.91% today, remaining in a consolidation phase, with a trading volume exceeding 84 million yuan, a 7% increase from the previous trading day [1]. - The ETF's closing premium rate was 0.06%, indicating ongoing investor attention, with two out of the last five days seeing inflows [1]. - The ETF's latest scale reached 2.598 billion yuan, leading its peers in the same category [1]. Stock Performance - Most constituent stocks of the Chinese Medicine ETF closed in the red, with notable declines including: - Pianzaihuang down 1.59% to 168.75 yuan, marking a five-year low [3]. - Yiling Pharmaceutical down over 3%, and Zhongsheng Pharmaceutical down over 2% [3]. - Conversely, stocks like Yunnan Baiyao and Jilin Aodong saw slight increases [3]. Valuation Metrics - As of December 3, the TTM price-to-earnings (PE) ratio for the ETF's index was 25.12, positioned at the 23.11% percentile over the past decade, suggesting that the index is cheaper than 76% of the time historically [5]. - The TTM PE is just 0.38 away from the calculated opportunity value, indicating a potential entry point for investors [5]. Historical Performance - The year-to-date return for the Chinese Medicine Index remains negative at -2.24%, with a decline of 8.13% projected for 2024 [7]. - The index has shown a pattern of consecutive declines, with four consecutive negative years if 2023 is considered a down year [7]. Demand Drivers - The recent flu outbreak has led to a significant increase in demand for respiratory medications, with flu cases reported rising by 53.8% compared to the previous week [9]. - The flu activity is at its highest level since 2022, which is expected to boost the demand for related medications [9]. Industry Outlook - Analysts from Zheshang Securities predict an inflection point for the Chinese medicine sector, suggesting that the sector will attract more investment due to its stable cash flow and lower volatility compared to other sectors [9]. - The industry is expected to see improved revenue and net profit growth in the second half of 2025, aided by reduced cost pressures from declining raw material prices [9].

中证报中证网讯（记者 罗京）12月3日，记者获悉，漳州片仔癀药业股份有限公司近日推出中药经典名 方——西黄丸，进一步丰富其以片仔癀、安宫牛黄丸等为核心的产品矩阵，标志着公司在肿瘤辅助治疗 领域的战略布局迈出重要一步。 在市场推广方面，片仔癀充分发挥自身渠道网络优势，目前已在全国超过300家片仔癀国药堂完成西黄 丸的铺货与销售。公司表示，片仔癀国药堂作为集中医药文化传播、专业服务与产品体验于一体的健康 服务平台，不仅为患者提供便捷购药渠道，还通过药师的专业指导，促进西黄丸的合理使用与科学普 及。 守正不泥古，创新不离宗。片仔癀表示，西黄丸的焕新上市，既是对中医药经典智慧的传承，也是片仔 癀以科技赋能传统中药、以产品服务大众健康的实践。在高质量发展道路上，公司将继续坚持创新驱动 与匠心制造，推动中医药在新时代焕发新的活力。 现代药理与临床研究显示，西黄丸在抑制肿瘤生长、调节免疫功能、缓解相关症状及减轻放化疗不良反 应等方面具有一定的辅助治疗价值。片仔癀表示，此次推出的西黄丸，在严格遵循古法配伍的基础上， 依托现代化制药技术实现品质升级。公司坚持"选材精良、匠心精制"，核心药材优选自道地产区，并严 格执行内控质量体 ...

Core Points - The Medical Health R Index (480016) closed at 7284.72 points, down 0.42%, with a trading volume of 17.046 billion yuan and a turnover rate of 0.61% [1] - Among the index constituents, 23 stocks rose while 26 fell, with TeBao Bio leading the gainers at 2.85% and Renfu Pharmaceutical leading the decliners at 3.33% [1] Index Constituents Summary - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 87.62, down 2.01%, and a market cap of 261.437 billion yuan [1] - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 60.97, down 0.25%, and a market cap of 404.670 billion yuan [1] - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 199.50, down 0.56%, and a market cap of 241.882 billion yuan [1] - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 128.88, up 0.13%, and a market cap of 106.217 billion yuan [1] - Pianzai Shou (sh600436) with a weight of 3.48%, latest price at 171.48, up 1.33%, and a market cap of 103.457 billion yuan [1] - Aier Eye Hospital (sz300015) with a weight of 3.42%, latest price at 11.35, down 1.30%, and a market cap of 105.843 billion yuan [1] - Kelun Pharmaceutical (sz002422) with a weight of 2.59%, latest price at 34.00, down 0.03%, and a market cap of 54.334 billion yuan [1] - Xinhecheng (sz002001) with a weight of 2.42%, latest price at 24.44, up 0.20%, and a market cap of 75.114 billion yuan [1] - Fosun Pharma (sh600196) with a weight of 2.39%, latest price at 27.05, down 0.15%, and a market cap of 72.235 billion yuan [1] - Ziji Shenzhou (sh688235) with a weight of 2.27%, latest price at 275.20, down 1.59%, and a market cap of 423.995 billion yuan [1] Capital Flow Analysis - The Medical Health R Index constituents experienced a net outflow of 1.159 billion yuan from institutional investors, while retail investors saw a net inflow of 999 million yuan [1] - Detailed capital flow for specific stocks shows: - Health元 (600380) had a net inflow of 34.2431 million yuan from institutional investors [2] - Hengrui Medicine (600276) had a net inflow of 29.9909 million yuan from institutional investors [2] - Long Spring High-tech (000661) had a net inflow of 19.8154 million yuan from institutional investors [2] - The index constituents underwent adjustments, adding four new stocks and removing one [2]

Core Viewpoint - The company Pizhou Pharmaceutical Co., Ltd. has been awarded the "2024 Golden Bull Most Investment Value Award," highlighting its strong comprehensive strength and sustained investment value in the competitive market [1][2]. Group 1: Award Recognition - The "Golden Bull Most Investment Value Award" is recognized as one of the most credible awards in the capital market, evaluated based on 18 key indicators across six dimensions, including enterprise scale and profitability [2]. - Pizhou has consistently received Golden Bull awards for several years, reflecting the high recognition of its comprehensive strength and long-term investment value by the judging panel [2]. Group 2: Investor Returns - The company emphasizes investor returns with a stable cash dividend policy, distributing a cash dividend of 2.97 yuan per share (including tax) for 2024, totaling 1.79 billion yuan, which is a historical high and accounts for 60% of net profit [3]. - This marks the 21st consecutive year of cash dividends since the company went public in 2003, with cumulative cash dividends nearing 8.5 billion yuan [3]. Group 3: Brand Value - As a time-honored brand, Pizhou has achieved a brand value of 42.289 billion yuan in 2024, ranking second among "Chinese Time-Honored Brands," with its brand value increasing year by year [4]. - The company has topped the "Hurun Brand List for Chinese Medical Health Brand Value" for four consecutive years and led the "Hurun China's Most Historical Cultural Heritage Brand List" for three times in 2024, showcasing its cultural depth and market influence [4][5]. Group 4: Innovation and Development - Pizhou adheres to innovation-driven development, with R&D investment reaching 270 million yuan in 2024, a year-on-year increase of 16.38% [6]. - The company is focusing on secondary development research of its advantageous products and accelerating the R&D of innovative traditional Chinese medicine and chemical drugs [6][7]. Group 5: ESG Performance - In terms of ESG (Environmental, Social, and Governance), Pizhou's performance has been recognized internationally, with its ESG rating upgraded from "BBB" to "A" by MSCI in 2024, indicating its management level is among the global industry leaders [7]. - The company has received multiple ESG-related awards, including "2024 Top 20 ESG Competitiveness of Chinese Pharmaceutical Listed Companies" and "ESG Value Transmission Award," reflecting the market's high recognition of its sustainable development capabilities [7][8]. Group 6: Future Outlook - Pizhou aims to use this award as a new starting point to continue its development philosophy of "Upholding Integrity and Innovation, Steady Progress," focusing on business expansion, R&D innovation, and brand building [8]. - The company plans to strengthen its core product advantages and expand its market presence in cosmetics, daily chemicals, and health food sectors, contributing to the health industry and creating greater value for investors [8][9].